In a phase 2 study investigating the combination of ofatumumab and CHOP in patients with untreated FL, the OR rate and complete response (CR) rate were similar to those previously reported for R-CHOP, but the rate of hematologic toxicity, specifically grade 3–4 neutropenia, was 90%, which is higher than that reported historically for R-CHOP [23]. This evidence concerns the gene DDIT3 and neutropenia.